Benchmark Reiterates Speculative Buy Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “speculative buy” rating reiterated by equities research analysts at Benchmark in a research note issued on Tuesday, Benzinga reports. They currently have a $17.00 target price on the stock. Benchmark’s price objective points to a potential upside of 431.25% from the stock’s current price.

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Reviva Pharmaceuticals in a research report on Monday, March 25th.

Reviva Pharmaceuticals Stock Down 3.9 %

NASDAQ RVPH opened at $3.20 on Tuesday. Reviva Pharmaceuticals has a fifty-two week low of $2.67 and a fifty-two week high of $9.25. The business has a 50 day moving average price of $3.71 and a two-hundred day moving average price of $4.18. The stock has a market cap of $89.34 million, a PE ratio of -1.95 and a beta of -0.02.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Raymond James & Associates acquired a new position in shares of Reviva Pharmaceuticals in the 1st quarter valued at approximately $34,000. Renaissance Technologies LLC bought a new stake in shares of Reviva Pharmaceuticals in the first quarter worth $31,000. BlackRock Inc. acquired a new stake in Reviva Pharmaceuticals in the third quarter valued at $133,000. Jane Street Group LLC bought a new position in Reviva Pharmaceuticals during the 3rd quarter valued at $27,000. Finally, Geode Capital Management LLC grew its holdings in Reviva Pharmaceuticals by 86.3% during the 4th quarter. Geode Capital Management LLC now owns 145,430 shares of the company’s stock worth $618,000 after acquiring an additional 67,355 shares in the last quarter. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.